Episode
Rare Disease Drug Commercialization With Zevra Therapeutics' Neil McFarlane
- Podcast
- Business Of Biotech
- Published
- May 25, 2026
- Duration seconds
- 3323
- Processing state
not_requested
Actions
POST https://stenobird.com/v1/public/podcasts/business-of-biotech-123501/episodes/rare-disease-drug-commercialization-with-zevra-therapeutics-neil-mcfarlane/transcription-requests
Idempotently request low-priority transcript generation for this episode.GET https://stenobird.com/podcast/business-of-biotech-123501/rare-disease-drug-commercialization-with-zevra-therapeutics-neil-mcfarlane.md
Read the agent-friendly Markdown representation of this episode resource.
Summary
We love to hear from our listeners. Send us a message. On this week's episode of the Business of Biotech, Neil McFarlane, CEO at Zevra Therapeutics, talks about transitioning to a focused rare disease company through acquisitions, and building out a commercial organization. Neil explains the importance of working with rare disease patient advocacy groups, using AI to analyze electronic health records and claims data to identify and diagnose patients with Niemann-Pick disease type C, and adap...